公开(公告)号：US20230212150A1

公开(公告)日：2023-07-06

申请号：US18062363

申请日：2022-12-06

Applicant: Gilead Sciences, Inc.

Inventor： Brian P. Bestvater ,  Joshua A. Kaplan ,  Barton W. Phillips ,  Kin S. Yang ,  Anna Zagorska

IPC: C07D401/14 ,  C07D401/04 ,  C07D413/14

CPC classification number: C07D401/14 ,  C07D401/04 ,  C07D413/14

Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).

公开(公告)号：US20230079863A1

公开(公告)日：2023-03-16

申请号：US17704440

申请日：2022-03-25

Applicant: Gilead Sciences, Inc.

Inventor： James L. Bachman ,  Daniel H. Byun ,  Christopher T. Clark ,  Petr Jansa ,  Joshua A. Kaplan ,  Zachary A. Kasun ,  Jennifer R. Lo ,  Megan E. Neubig ,  Nathaniel H. Stanley ,  Kirk L. Stevens

IPC: C07D409/14 ,  C07D405/14 ,  C07D403/14 ,  C07D401/14 ,  C07D495/04 ,  C07D513/04 ,  C07D493/10 ,  C07D491/107 ,  C07D413/14 ,  C07D403/04 ,  A61K45/06

Abstract: Compounds of formula: wherein the variable substituents are defined herein.

公开(公告)号：US20160096827A1

公开(公告)日：2016-04-07

申请号：US14863108

申请日：2015-09-23

Applicant: Gilead Sciences, Inc.

Inventor： Zhimin Du ,  Juan A. Guerrero ,  Joshua A. Kaplan ,  John E. Knox, JR. ,  Jennifer R. Lo ,  Scott A. Mitchell ,  Devan Naduthambi ,  Barton W. Phillips ,  Chandrasekar Venkataramani ,  Peiyuan Wang ,  William J. Watkins ,  Zhongdong Zhao

IPC: C07D405/12 ,  C07D405/14 ,  A61K31/53 ,  C07D403/14 ,  C07D409/14 ,  A61K31/5383 ,  A61K31/5377 ,  C07D417/14 ,  C07D491/107 ,  C07D471/10 ,  C07D413/14 ,  C07D498/04 ,  A61K31/541 ,  C07D403/12

CPC classification number: C07D405/12 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/541 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107 ,  C07D491/113 ,  C07D498/04

Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:

公开(公告)号：US12161625B2

公开(公告)日：2024-12-10

申请号：US18059806

申请日：2022-11-29

Applicant: Gilead Sciences, Inc.

Inventor： Jinfa Du ,  Joshua A. Kaplan ,  Thorsten A. Kirschberg ,  Tetsuya Kobayashi ,  Scott E. Lazerwith ,  Rick Andrew Lee ,  Jonathan William Medley ,  Michael L. Mitchell ,  Philip Anthony Morganelli ,  Hyung-Jung Pyun ,  Sophia L. Shevick ,  Neil H. Squires ,  William J. Watkins

IPC: A61K31/403 ,  A61K31/03 ,  A61K31/16 ,  A61K31/38 ,  A61K31/4192 ,  A61P31/20 ,  C07D487/04 ,  C07D519/00

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

公开(公告)号：US11980609B2

公开(公告)日：2024-05-14

申请号：US17741222

申请日：2022-05-10

Applicant: Gilead Sciences, Inc.

Inventor： Brian P. Bestvater ,  Joshua A. Kaplan ,  Megan E. Neubig ,  Kin S. Yang ,  Anna Zagorska

IPC: A61K31/4155 ,  C07D231/40 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04

CPC classification number: A61K31/4155 ,  C07D231/40 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04

Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (TLD), or chronic kidney disease (CKD).

公开(公告)号：US20230212151A1

公开(公告)日：2023-07-06

申请号：US18062469

申请日：2022-12-06

Applicant: Gilead Sciences, Inc.

Inventor： Brian P. Bestvater ,  Zhimin Du ,  Julie Farand ,  Joshua A. Kaplan ,  Barton W. Phillips ,  Doris T. Tang ,  Chandrasekar Venkataramani ,  Peiyuan Wang ,  Kin S. Yang ,  Anna Zagorska

IPC: C07D401/14 ,  C07D413/14

CPC classification number: C07D401/14 ,  C07D413/14

Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).

公开(公告)号：US10040781B2

公开(公告)日：2018-08-07

申请号：US14863108

申请日：2015-09-23

Applicant: Gilead Sciences, Inc.

Inventor： Zhimin Du ,  Juan A. Guerrero ,  Joshua A. Kaplan ,  John E. Knox, Jr. ,  Jennifer R. Lo ,  Scott A. Mitchell ,  Devan Naduthambi ,  Barton W. Phillips ,  Chandrasekar Venkataramani ,  Peiyuan Wang ,  William J. Watkins ,  Zhongdong Zhao

IPC: C07D405/12 ,  C07D403/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D491/113 ,  C07D498/04 ,  C07D403/14 ,  C07D491/107 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/541

Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:

公开(公告)号：US20230270719A1

公开(公告)日：2023-08-31

申请号：US18059806

申请日：2022-11-29

Applicant: Gilead Sciences, Inc.

Inventor： Jinfa Du ,  Joshua A. Kaplan ,  Thorsten A. Kirschberg ,  Tetsuya Kobayashi ,  Scott E. Lazerwith ,  Rick Andrew Lee ,  Jonathan William Medley ,  Michael L. Mitchell ,  Philip Anthony Morganelli ,  Hyung-Jung Pyun ,  Sophia L. Shevick ,  Neil H. Squires ,  William J. Watkins

IPC: A61K31/403 ,  C07D487/04 ,  C07D519/00 ,  A61P31/20 ,  A61K31/03 ,  A61K31/16 ,  A61K31/38 ,  A61K31/4192

CPC classification number: A61K31/403 ,  C07D487/04 ,  C07D519/00 ,  A61P31/20 ,  A61K31/03 ,  A61K31/16 ,  A61K31/38 ,  A61K31/4192

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

公开(公告)号：US11584738B2

公开(公告)日：2023-02-21

申请号：US17319507

申请日：2021-05-13

Applicant: Gilead Sciences, Inc.

Inventor： Brian P. Bestvater ,  Zhimin Du ,  Julie Farand ,  Joshua A. Kaplan ,  Barton W. Phillips ,  Doris T. Tang ,  Chandrasekar Venkataramani ,  Peiyuan Wang ,  Kin S. Yang ,  Anna Zagorska

IPC: C07D401/14 ,  C07D409/14 ,  C07D405/14

Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).

公开(公告)号：US20220411405A1

公开(公告)日：2022-12-29

申请号：US17741222

申请日：2022-05-10

Applicant: Gilead Sciences, Inc.

Inventor： Brian P. Bestvater ,  Joshua A. Kaplan ,  Megan E. Neubig ,  Kin S. Yang ,  Anna Zagorska

IPC: C07D401/14 ,  C07D231/40 ,  C07D401/04 ,  C07D403/04

Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (TLD), or chronic kidney disease (CKD).